← Back to Search

Radiolabeled Monoclonal Antibody for Non-Hodgkin's Lymphoma

Phase 3

Waitlist Available

Research Sponsored by Gilead Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No second primary malignancy within past 5 years other than adequately treated in situ carcinoma of the cervix or uterus, or basal or squamous cell carcinoma of the skin

No prior exposure to mouse antibodies other than technetium Tc 99m LL2 monoclonal antibody

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well a radiolabeled monoclonal antibody works in detecting and staging non-Hodgkin's lymphoma.

Who is the study for?

This trial is for individuals aged 16 or older with B-cell non-Hodgkin's lymphoma, who can perform daily activities (ECOG 0-2). They must not be allergic to mouse proteins, have had no other cancers in the last 5 years except certain skin or cervical/uterine cancers, and should not have been treated with mouse antibodies before. Participants need functioning kidneys and are not allowed to join other medical studies concurrently.Check my eligibility

What is being tested?

The study is testing a radiolabeled monoclonal antibody's effectiveness in detecting and determining the stage of non-Hodgkin's lymphoma. It’s a Phase III trial which means it’s looking at how well this method works compared to current standard practices.See study design

What are the potential side effects?

Potential side effects may include allergic reactions due to mouse protein components of the monoclonal antibody, as well as typical risks associated with exposure to radiation used in diagnostic imaging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I haven't had any other cancer except for certain skin cancers or treated cervical/uterine cancer in the last 5 years.

Select...

I have not been treated with mouse antibodies, except for technetium Tc 99m LL2.

Select...

I am 16 years old or older.

Select...

My lymphoma is a type of B-cell non-Hodgkin's lymphoma.

Select...

I can take care of myself and perform daily activities.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor

1,082 Previous Clinical Trials

842,741 Total Patients Enrolled

44 Trials studying Lymphoma

3,185 Patients Enrolled for Lymphoma

William A. Wegener, MD, PhDStudy ChairGilead Sciences

1 Previous Clinical Trials

60 Total Patients Enrolled

1 Trials studying Lymphoma

60 Patients Enrolled for Lymphoma

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00003337 — Phase 3

Lymphoma Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00003337 — Phase 3

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003337 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially take part in this research project?

"This study is only for people that currently have lymphoma and are between 16 and 120 years old. Out of the 100 patients that will be recruited, how many will you be able to help us with?"

Answered by AI

Are minors eligible for this research program?

"Enrollment for this particular trial is only available to patients aged 16 to 120. There are 315 other trials for patients that are underaged and 1619 trials for senior citizens."

Answered by AI

How many places are currently testing this out?

"There are 4 sites enrolling patients for this clinical trial. 3 of these locations are in major cities: Baltimore, Houston and Los Angeles. The other 4 sites are more spread out, so please choose the one closest to you to limit travel time and costs."

Answered by AI

Has this course of action been accepted by the Federal Drug Administration?

"There is some evidence supporting the efficacy of this treatment and it has undergone multiple rounds of testing, so the Power team has given it a safety rating of 3."

Answered by AI

Is this research still enrolling people who are sick?

"As can be gleaned from clinicaltrials.gov, this trial is not currently looking for patients. The study was initially posted on 3/1/1997 and was most recently updated on 8/12/2021. Although this particular trial is not seeking patients anymore, there are 1782 other studies that are."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma

1997. "Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00003337.

All > Childhood Leukemia > Lymphoma